Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00652223 |
Recruitment Status :
Completed
First Posted : April 3, 2008
Last Update Posted : April 9, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Perennial Allergic Rhinoconjunctivitis Allergic Asthma | Biological: CYT005-AllQbG10 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 21 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (AllQbG10) in Subjects With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy |
Study Start Date : | March 2005 |
Actual Study Completion Date : | November 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: 1 |
Biological: CYT005-AllQbG10
Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites
- Mild asthma
- Females only if non-reproductive or agree to practice an effective and accepted method of contraception
Exclusion Criteria:
- Relevant cardiovascular, renal, pulmonary or endocrine disease
- History of autoimmune disease
- Severe allergies
- History of active infectious disease
- Current diagnosis or history of malignancy
- Relevant neurological or psychiatric disorder
- Pregnancy or lactation
- History of alcohol abuse or other recreational drugs
- Use of an investigational drug within three month before enrolment
- Blood donation within 30 days before enrolment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00652223
Switzerland | |
University Hospital Zurich, Department of Dermatology | |
Zurich, Switzerland, 8091 |
Study Director: | Philipp Mueller, MD | Cytos Biotechnology AG |
ClinicalTrials.gov Identifier: | NCT00652223 |
Other Study ID Numbers: |
CYT005-AllQbG10 01 |
First Posted: | April 3, 2008 Key Record Dates |
Last Update Posted: | April 9, 2008 |
Last Verified: | April 2008 |
Asthma Conjunctivitis Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Conjunctival Diseases Eye Diseases |